Страна: Австралия
Език: английски
Източник: APVMA (Australian Pesticides and Veterinary Medicines Authority)
FLUOXETINE HYDROCHLORIDE
REDCAP SOLUTIONS PTY LTD
fluoxetine as HCl(8mg/Tb)
ORAL TABLET
FLUOXETINE HYDROCHLORIDE UNGROUPED Active 8.0 mg
30 Tablets
VM - Veterinary Medicine
NEXCYON PHARMACEUTIC
DOG | BITCH | CASTRATE | PUPPY
CENTRAL NERVOUS SYSTEM
ANXIETY DISORDER
Poison schedule: 4; Withholding period: WHP: N/A; Host/pest details: DOG: [ANXIETY DISORDER]; Poison schedule: 4; Withholding period: ; Host/pest details: DOG: [ANXIETY DISORDER]; For use as an aid in the treatment of canine separation anxiety and reduction of associated behaviours in conjunction with a behaviour modification plan in dogs.Do not use in dogs with a history of epilepsy or history of seizures. See label for other details and precautions.
Registered
2023-07-01
®® ® SH8720DEALX (V01-10-2009) CA4203 SH8720DEALX Chewable Tablets for Dogs Chewable Tablets for Dogs ACTIVE CONSTITUENT: Each tablet contains 8 mg fluoxetine (as fluoxetine hydrochloride). PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY FOR USE AS AN AID IN THE TREATMENT OF CANINE SEPARATION ANXIETY AND REDUCTION OF ASSOCIATED BEHAVIOURS IN CONJUNCTION WITH A BEHAVIOUR MODIFICATION PLAN IN DOGS WEIGHING 4 TO 8 KG. 30 TABLETS 8 mg 8 mg READ THE ENCLOSED LEAFLET BEFORE USING THIS PRODUCT DIRECTIONS FOR USE THESE TABLETS MUST BE DISPENSED IN A CHILD-RESISTANT CONTAINER. CONTRAINDICATIONS RECONCILE CHEWABLE TABLETS ARE CONTRAINDICATED IN DOGS WITH EPILEPSY OR A HISTORY OF SEIZURES. RECONCILE TABLETS SHOULD NOT BE GIVEN CONCOMITANTLY WITH DRUGS THAT LOWER THE SEIZURE THRESHOLD (EG. PHENOTHIAZINES SUCH AS ACEPROMAZINE OR CHLORPROMAZINE). RECONCILE CHEWABLE TABLETS ARE CONTRAINDICATED IN DOGS WITH A KNOWN HYPERSENSITIVITY TO FLUOXETINE HYDROCHLORIDE OR OTHER SSRI’S (SELECTIVE SEROTONIN REUPTAKE INHIBITORS). RECONCILE CHEWABLE TABLETS SHOULD NOT BE GIVEN IN COMBINATION WITH MONOAMINE OXIDASE INHIBITOR (MAOI) [E.G. SELEGILINE HYDROCHLORIDE (L-DEPRENYL) OR AMITRAZ], OR WITHIN A MINIMUM OF 14 DAYS OF DISCONTINUING THERAPY WITH AN MAOI. BECAUSE FLUOXETINE AND ITS MAJOR METABOLITES, NORFLUOXETINE, HAVE LONG HALF-LIVES, A 6-WEEK WASHOUT INTERVAL SHOULD BE OBSERVED FOLLOWING DISCONTINUATION OF THERAPY WITH RECONCILE CHEWABLE TABLETS PRIOR TO THE ADMINISTRATION OF ANY DRUG THAT MAY ADVERSELY REACT WITH FLUOXETINE OR NORFLUOXETINE. PRECAUTIONS: RECONCILE Chewable tablets have not been evaluated for the treatment of other behavioural disorders. RECONCILE Chewable tablets are not recommended for the treatment of aggression. The safety of RECONCILE Chewable Tablets in dogs less than 6 months of age or in dogs weighing less than 4kg has not been evaluated as no studies have been conducted. The safety of RECONCILE Chewable Tablets in breeding, pregnant or lactating dogs has not been evaluated a Прочетете целия документ